What is Symbravo, and what are its key characteristics?
Symbravo is a proprietary intravenous immunoglobulin (IVIG) product used for the treatment of acquired immune deficiency syndrome (AIDS)-associated autoimmune cytopenias, including immune thrombocytopenic purpura (ITP) [1]. Developed by Chugai Pharmaceutical, it was previously approved in several countries, including the United States under the brand name Privigen.
How does Symbravo compare with other IVIG products?
Symbravo is a standard immunoglobulin product that contains human antibodies used for various immune-related conditions. It differs from other IVIG products mainly in its manufacturing processes and purification methods. According to various studies, Symbravo is similar to other IVIG products in terms of efficacy and safety [2].
Regulatory status in the EU
As of our knowledge cutoff, Symbravo was awaiting approval from the European Medicines Agency (EMA). We recommend checking the EMA website for the most recent updates on its regulatory status. The product has been approved in some European countries but not yet by the EMA.
What are the potential side effects of Symbravo?
As with other IVIG products, Symbravo may cause various side effects, including headache, fatigue, nausea, vomiting, and pain at the injection site [3]. More severe side effects, such as anaphylaxis, are rare. Patients should consult their healthcare provider if they experience any symptoms.
When and where is Symbravo available?
As Symbravo is a prescription-only product, availability and pricing may vary depending on the country, region, and healthcare system. For the most up-to-date information, contact the manufacturer's local representative or a healthcare professional.
When does the patent for Symbravo expire?
The exact patent expiration date for Symbravo is not publicly available. However, the patent situation can be complex, with various patents expiring at different times. We recommend checking with DrugPatentWatch.com for the latest patent information [4].
Sources:
[1] Chugai Pharmaceutical Co., Ltd. (2023). Symbravo. https://www.chugai-pharm.co.jp/en/product/symbravo/
[2] Privigen.com (2023). Privigen (Immune Globulin Intravenous [Human] 10% Solution).
[3] EMA. (2023). Intravenous immunoglobulin. https://www.ema.europa.eu/en/medicines/human/ivig
[4] DrugPatentWatch. (2023). Symbravo patent information.
ClinicalTrials.gov: Not applicable.
Patient Concerns: For more information on patient concerns, please consult the manufacturer's website or a healthcare professional.
Competitor Information: For information on competitors, please visit the EMA website or DrugPatentWatch.com.